Treatment with 300-mg secukinumab confers benefits among patients with palmoplantar pustular psoriasis (PPP) in terms of Palmoplantar Psoriasis Area and Severity Index (PPPASI75) responses over 52 weeks and improved quality of life (QOL), results of the 2PRECISE study have shown.
Patients with moderate-to-severe atopic dermatitis (AD) were more likely to have clinically meaningful responses when treated with dupilumab at doses of 300 mg either weekly or every 2 weeks compared with those on placebo, according to a post hoc analysis of the phase III SOLO 1 and SOLO 2* trials presented as a poster at AAD 2019.
The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).
The humanized immunoglobulin G1 monoclonal antibody risankizumab provided durable clinical efficacy compared with ustekinumab in individuals with moderate-to-severe plaque psoriasis, according to integrated analyses of UltIMMa-1 and 2* presented at AAD 2019.
Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.
Results of a Singapore study have shown the effectiveness of a structure pharmacist-led cessation counselling in reducing smoking rates. Smoking cessation can thus be made a part of the holistic management of dermatological conditions.
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
Olumacostat glasaretil (OG) appears to be effective and is well tolerated in patients with moderate to severe facial acne vulgaris, suggesting the need for further development, according to a new study.
Cost of treatment is a major driver of patients’ primary nonadherence to acne medication, according to a recent study. Physicians who openly discuss medications costs and provide a plan of action in case patients are unable to fill prescriptions may improve treatment adherence.
New topical formulation BiRetix gel Ultra (BR gel) is effective and well tolerated in individuals with mild to moderate acne, reducing both noninflammatory (NI-L) and inflammatory acne lesions (IL), a recent study has found. In addition, BR gel has good skin tolerability and can be considered as first-line treatment for predominant comedonal.